Logo

American Heart Association

  2
  0


Final ID: TP286

Atrial Fibrillation Predictors on Insertable Cardiac Monitor: The ANTARCTICA Study

Abstract Body: Introduction:
Atrial Fibrillation (AF) is detected in nearly 30% of patients undergoing cardiac monitoring after ischemic stroke. Studies investigating predictors of AF showed mixed results. In this study, we aim to identify predictors of AF on insertable cardiac monitors (ICMs) and compare rates between cryptogenic stroke patients and controls.

Methods:
The ANTicoagulation And StRoke ReCurrence in ATrial FIbrillation DeteCted After Stroke (ANTARCTICA) study is an individual patient data meta-analysis of prospective observational studies of cryptogenic ischemic stroke and control patients (non-cryptogenic ischemic stroke and non-ischemic stroke) who underwent an ICM implantation. The search included prospective observational studies and randomized controlled trials of patients with non-cardioembolic ischemic stroke or transient ischemic attack or non-ischemic stroke controls who underwent prolonged cardiac monitoring with an ICM after the index event. We performed multiple imputations to derive missing covariates such as left atrial volume index. We used multivariable multi-level logistic regression models to identify clinical, imaging, and echocardiographic factors associated with AF detection. We compared AF rates and charecterisctis between cryptogenic stroke and controls.

Results:
We identified 14 studies (2 RCTs and 12 observational) that included 2036 patients (1562 cryptogenic stroke and 474 non-cryptogenic stroke and non stroke controls); AF was detected in 30.7% of cryptogenic stroke patients and 29.1% of non-cryptogenic stroke patients. In multivariable logistic regression analyses, factors associated with AF were age (OR per year increase 1.05 95% CI 1.04-1.06), left atrial volume index (OR per unit increase 1.03 95% CI 1.02-1.05), and cryptogenic stroke (adjusted OR 1.89, 95% CI 1.20-2.98, p = 0.006). When compared to controls, the time to AF detection was significantly shorter in cryptogenic stroke (median 65 days vs. 169 days, p < 0.001) and AF duration was non-significantly longer (median 90 minutes vs. 120 minutes, p = 0.144). Results remained unchanged when the control group was limited to patients with non-cryptogenic ischemic stroke.

Conclusions:
In this large, individual patient data meta-analysis of patients undergoing ICM, there is increased detection and burden of AF after cryptogenic stroke compared to controls, suggesting a likely pathogenicity of device-detected AF in cryptogenic stroke.
  • Yaghi, Shadi  ( Brown University , Providence , Rhode Island , United States )
  • Greisenegger, Stefan  ( Department of Neurology, Medical Un , Vienna , Austria )
  • Nahab, Fadi  ( EMORY UNIVERSITY , Atlanta , Georgia , United States )
  • Alshaer, Qasem  ( EMORY UNIVERSITY , Atlanta , Georgia , United States )
  • Kitsiou, Alkisti  ( EVKB , Bielefeld , Germany )
  • Tsivgoulis, Georgios  ( Neurodiagnostics PC , Athens , Greece )
  • Skrebelyte-strom, Loreta  ( Oslo University Hospital , Oslo , Norway )
  • Lambert, Anna Tancin  ( Oslo University Hospital , Oslo , Norway )
  • Ronning, Ole Morten  ( Oslo University Hospital , Oslo , Norway )
  • Hege Aamodt, Anne  ( Oslo University Hospital , Oslo , Norway )
  • Bufano, Gabriella  ( University of Cheiti , Pescara , Italy )
  • Fridman, Sebastian  ( Western University , London , Ontario , Canada )
  • Renda, Giulia  ( University of Cheiti , Pescara , Italy )
  • Cuadrado, Elisa  ( UPF , Barcelona , Spain )
  • Pikija, Slaven  ( PMU , Salzburg , Austria )
  • Buck, Brian  ( University of Alberta , Edmonton , Alberta , Canada )
  • Ondraskova, Eva  ( McMaster University , Hamilton , Ontario , Canada )
  • Healey, Jeffrey  ( McMaster University , Hamilton , Ontario , Canada )
  • Mcintyre, William  ( McMaster University , Hamilton , Ontario , Canada )
  • Hill, Michael  ( UNIVERSITY CALGARY , Calgary , Alberta , Canada )
  • Saver, Jeffrey  ( GEFFEN SCHOOL OF MEDICINE AT UCLA , Los Angeles , California , United States )
  • Kasner, Scott  ( UPENN , Philadelphia , Pennsylvania , United States )
  • Shu, Liqi  ( Brown University , Providence , Rhode Island , United States )
  • Kamel, Hooman  ( Weill Cornell Medicine , New York , New York , United States )
  • Elkind, Mitchell  ( American Heart Association , New York , New York , United States )
  • Kent, David  ( Tufts University , Boston , Massachusetts , United States )
  • Katsanos, Aristeidis  ( McMaster University , Hamilton , Ontario , Canada )
  • Sposato, Luciano  ( Western University , London , Ontario , Canada )
  • Garcia-rodriguez, Daniel  ( Hospital Puerta de Hierro , Majadahonda , Spain )
  • Castro, Victor  ( CPH , Madrid , Spain )
  • Kreimer, Fabienne  ( RUHR-UNIVERSITÄT BOCHUM , BOCHUM , Germany )
  • Gotzmann, Michael  ( RUHR-UNIVERSITÄT BOCHUM , BOCHUM , Germany )
  • Koge, Jumpei  ( NCVC , Osaka , Japan )
  • Ikenouchi, Hajime  ( NCVC , Osaka , Japan )
  • Author Disclosures:
    Shadi Yaghi: DO NOT have relevant financial relationships | Stefan Greisenegger: DO NOT have relevant financial relationships | Fadi Nahab: DO NOT have relevant financial relationships | Qasem AlShaer: DO NOT have relevant financial relationships | Alkisti Kitsiou: DO NOT have relevant financial relationships | Georgios Tsivgoulis: DO NOT have relevant financial relationships | Loreta Skrebelyte-Strom: DO NOT have relevant financial relationships | Anna Tancin Lambert: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Medtronic:Past (completed) | Ole Morten Ronning: DO NOT have relevant financial relationships | Anne Hege Aamodt: No Answer | Gabriella Bufano: DO NOT have relevant financial relationships | SEBASTIAN FRIDMAN: No Answer | GIULIA RENDA: DO have relevant financial relationships ; Research Funding (PI or named investigator):Bayer:Past (completed) ; Speaker:Menarini:Past (completed) ; Speaker:Boehringer Ingelheim:Past (completed) ; Speaker:Bayer:Past (completed) ; Research Funding (PI or named investigator):BMS-Janssen:Active (exists now) | Elisa Cuadrado: DO NOT have relevant financial relationships | Slaven Pikija: No Answer | Brian Buck: DO NOT have relevant financial relationships | Eva Ondraskova: DO NOT have relevant financial relationships | JEFFREY HEALEY: No Answer | William McIntyre: DO have relevant financial relationships ; Consultant:Atricure:Past (completed) ; Research Funding (PI or named investigator):Trimedics:Active (exists now) ; Speaker:iRhythm:Past (completed) ; Consultant:Trimedics:Active (exists now) | Michael Hill: DO have relevant financial relationships ; Consultant:Brainsgate Inc:Past (completed) ; Individual Stocks/Stock Options:Circle Inc:Active (exists now) ; Individual Stocks/Stock Options:Basking Bioscience:Active (exists now) ; Research Funding (PI or named investigator):Boehringer-Ingelheim:Active (exists now) ; Research Funding (PI or named investigator):Medtronic:Active (exists now) ; Consultant:Diamedica Inc:Active (exists now) | Jeffrey Saver: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Individual Stocks/Stock Options:Viz.ai:Active (exists now) ; Individual Stocks/Stock Options:Let's Get Proof:Active (exists now) ; Individual Stocks/Stock Options:Neuronics:Active (exists now) ; Consultant:Genentech:Expected (by end of conference) ; Consultant:Roche:Active (exists now) ; Consultant:Novo Nordisc:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:BrainQ:Active (exists now) ; Consultant:Medtronic:Active (exists now) | Scott Kasner: DO have relevant financial relationships ; Researcher:WL Gore:Active (exists now) ; Consultant:Bristol-Myers Squibb:Active (exists now) ; Researcher:DiaMedica:Active (exists now) ; Researcher:Bayer:Active (exists now) ; Royalties/Patent Beneficiary:UpToDate:Active (exists now) | Liqi Shu: DO NOT have relevant financial relationships | Hooman Kamel: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Financial disclosures for Hooman Kamel: a PI role in the ARCADIA trial, which received in-kind study drug from the BMS-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics; a Deputy Editor role for JAMA Neurology; clinical trial steering/executive committee roles for the STROKE-AF (Medtronic), LIBREXIA-AF (Janssen), and LAAOS-4 (Boston Scientific) trials; consulting or endpoint adjudication committee roles for AbbVie, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk; and household ownership interests in TETMedical, Spectrum Plastics Group, and Ascential Technologies.:Active (exists now) | Mitchell Elkind: DO have relevant financial relationships ; Research Funding (PI or named investigator):Roche:Past (completed) ; Employee:American Heart Association:Active (exists now) ; Speaker:Atria Academy of Science and Medicine:Past (completed) ; Research Funding (PI or named investigator):BMS-Pfizer Alliance for Eliquis:Past (completed) | David Kent: No Answer | Aristeidis Katsanos: DO NOT have relevant financial relationships | Luciano Sposato: No Answer | Daniel Garcia-Rodriguez: DO NOT have relevant financial relationships | Victor Castro: No Answer | Fabienne Kreimer: No Answer | Michael Gotzmann: DO NOT have relevant financial relationships | Jumpei Koge: No Answer | Hajime Ikenouchi: DO NOT have relevant financial relationships
Meeting Info:
Session Info:

Risk Factors and Prevention Posters II

Thursday, 02/06/2025 , 07:00PM - 07:30PM

Poster Abstract Session

More abstracts on this topic:
A First-in-Class Humanized Antibody Fragment Targeting Platelet Glycoprotein Ibα: A Comprehensive Preclinical Study of CA1001 for the Treatment of Acute Ischemic Stroke

Xu Xiaohong, Preeti Preeti, Yu Ruoying, Shaykhalishahi Hamed, Zhang Cheng, Shen Chuanbin, Li Bei, Tang Naping, Chang Yan, Xiang Qian, Cui Yimin, Lei Xi, Ni Heyu, Zhu Guangheng, Liu Zhenze, Hu Xudong, Slavkovic Sladjana, Neves Miguel, Ma Wenjing, Xie Huifang

A Comparative Analysis of Esophageal Cooling for Preventing Esophageal Injury Post Atrial Fibrillation Catheter Ablation: A Systematic Review and Meta-analysis

Ibrahim Momen Mohamed, Al Hennawi Hussam, Tanas Yousef, Abourady Youmna, Sewedan Nourhan, Hashem Ahmed Magdy, Motawea Karam R.

More abstracts from these authors:
Anticoagulation versus Antiplatelets Across Subgroups of Embolic Stroke of Undetermined Source: A Meta-Analysis of Seven Randomized Controlled Trials

Ghannam Malik, Elkind Mitchell, Tirschwell David, Poli Sven, Kamel Hooman, Yaghi Shadi, Al-qudah Abdullah, Alshaer Qasem, Kronmal Richard, Ntaios George, Longstreth W, Furie Karen, Saver Jeffrey, Kasner Scott

Recurrent Strokes in the ARCADIA Trial

Tirschwell David, Elkind Mitchell, Kamel Hooman, Kronmal Richard, Longstreth W

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)